Results 41 to 50 of about 4,156,285 (177)

Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis

Journal of the Formosan Medical Association, 2022
Background: The risk of hepatocellular carcinoma (HCC) is reduced but not eliminated after nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB).
Tung-Hung Su, Cheng-Yuan Peng, Shan-Han Chang, Tai-Chung Tseng, Chun-Jen Liu, Chi-Ling Chen, Chen-Hua Liu, Hung-Chih Yang, Pei-Jer Chen, Jia-Horng Kao   +9 more
doaj   +1 more source

The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. [PDF]

, 2021
Prothrombin induced by vitamin K absence II (PIVKA-II) has recently been validated internationally as a diagnostic biomarker for hepatocellular carcinoma (HCC), as part of the GALAD model. However, its role as a treatment response biomarker has been less
Curbishley, Stuart, Fletcher, Peter, Ma, Yuk Ting, Herring, Kathyrn, Shah, Tahir, Mehrzad, Homoyon, Shetty, Shishir; id_orcid, Karkhanis, Salil, Punia, Pankaj, Hodson, James, Sagar, Vandana M, Ma, Yuk Ting; id_orcid, Shetty, Shishir   +12 more
core   +1 more source

The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantation in a Low Alpha-Fetoprotein Population. [PDF]

Cancers (Basel), 2023
Introduction: AFP and the RETREAT score are currently used to predict HCC recurrence after LT. However, superior discriminating models are needed for low AFP populations.
Devillers MJC, Pluimers JKF, van Hooff MC, Doukas M, Polak WG, de Man RA, Sonneveld MJ, Boonstra A, den Hoed CM.   +8 more
europepmc   +2 more sources

Clinical evaluation of serum PIVKA-II in small hepatocellular carcinomas using a sensitive PIVKA-II assay.

Kanzo, 2000
腫瘍径3cm以下の小肝細胞癌82症例 (針生検例44例, 外科的切除例38例) に対し高感度PIVKA-II測定の意義について検討した. PIVKA-II陽性率は腫瘍径3.0cm以下で34%, 2.0cm以下で21%であった.
KAMADA, Koji, KITAMOTO, Mikiya, AIKATA, Hiroshi, KAWAKAMI, Yoshiiku, TAKAHASHI, Shoichi, OHISHI, Waka, MATSUMOTO, Akiko, SHIGEMI, Keiko, TAKAISHI, Hideki, ISHIHARA, Hiroto, OHBATAKE, Toshiyuki, NAKANISHI, Toshio, ITAMOTO, Toshiyuki, ASAHARA, Toshimasa, SHIMAMOTO, Fumio, KAJIYAMA, Goro   +15 more
openaire   +3 more sources

Estudio del PIVKA-II y de otros marcadores angiogénicos y metastásicos en el trasplante hepático por hepatocarcinoma [PDF]

, 2022
El hepatocarcinoma (CHC) representa entre el 75-85% del total de neoplasias ocurrentes en el hígado. El trasplante ortotópico de hígado (TOH) es la mejor opción de tratamiento, ya que podría curar simultáneamente el tumor y la cirrosis subyacente.
Villalba López, Francisco
core  

Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K-1) in severe acute liver disease

, 2005
Background/Aims: In patients with severe acute liver dysfunction, i.v. phylloquinone (vitamin K-1) may be given to exclude vitamin K deficiency, rather than impaired hepatic synthesis of coagulation factors alone, as the cause of the coagulopathy ...
Pereira, SP, David Rowbotham, Stephen P. Pereira, Sarah Fitt, Fitt, S, Pereira, S P, Wendon, J, Roger Williams, Williams, R, Julia Wendon, Rowbotham, D, Martin J. Shearer, Shearer, MJ, Shearer, M J   +13 more
core   +1 more source

PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC [PDF]

International Journal of Molecular Sciences
Antonella Farina, Patrizia Mancini, Antonio Angeloni   +2 more
exaly   +2 more sources

Unclassified hepatocellular adenoma with histological brown pigment deposition and serum PIVKA-II level elevation: a case report

Surgical Case Reports, 2020
Background Hepatocellular adenoma (HCA) is conventionally considered a rare benign liver tumor, but advanced studies have revealed that HCA is heterogeneous, and may include a type that is prone to malignant transformations.
Kouki Hoshino, Norifumi Harimoto, Ryo Muranushi, Kei Hagiwara, Takahiro Yamanaka, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Norio Kubo, Kenichiro Araki, Ran Tomomasa, Sumihito Nobusawa, Shinichi Aishima, Osamu Nakashima, Ken Shirabe   +15 more
doaj   +1 more source

Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma Combined Biomarker-Guided EMT Tracking in PDAC. [PDF]

Cancers (Basel)
Simple Summary Protein Induced by Vitamin K Absence (PIVKA II), also known as Des-gamma-Carboxy prothrombin (DCP), is an established tumor marker for hepatocellular carcinoma (HCC) and a good diagnostic performance has also been demonstrated for ...
Farina A, Viggiani V, Cortese F, Moretti M, Tartaglione S, Angeloni A, Anastasi E.   +6 more
europepmc   +2 more sources

Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication

Journal of Clinical Laboratory Analysis, EarlyView.
Up‐to‐date, tumor markers are considered more helpful in the evaluation of treatment response and prognostication rather than diagnosis. Identifying a valid biomarker to help clinical management of hepatocellular carcinoma (HCC) is still a challenge, especially the alpha‐fetoprotein (AFP) negative HCC. This study evaluated the efficacy of serum Midkine
Yanfang Luo, Qiuwei Lu, Jing Huang, Liejun Jiang   +3 more
wiley   +1 more source